Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clindamycin phosphate, quantity: 0 qs (equivalent: clindamycin, qty 150 mg/ml) - injection, solution - excipient ingredients: disodium edetate; hydrochloric acid; water for injections; sodium hydroxide; benzyl alcohol - indications as at 20 june 2005 : dalacin c phosphate is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. dalacin c phosphate is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin - allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes - serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract) and infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection, all when given in conjunction with an antibiotic of appropriate g

Malta - English - Medicines Authority

baxter healthcare limited - calcium chloride, dihydrate, potassium chloride, sodium chloride, sodium lactate - solution for infusion - calcium chloride dihydrate 0.27 gram(s)/litre ; potassium chloride 0.4 gram(s)/litre ; sodium chloride 6 gram(s)/litre ; sodium lactate 3.2 gram(s)/litre - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - fludarabine phosphate - powder for solution for infusion or injection - fludarabine phosphate 50 mg - antineoplastic agents

Malta - English - Medicines Authority

b braun melsungen ag carl-braun-strasse 1, d34212 melsungen, germany - calcium chloride, dihydrate, phenylalanine, potassium acetate, histidine, arginine, aspartic acid, threonine, triglycerides medium, chain, valine, zinc acetate, glucose, glutamic acid, glycine, methionine, isoleucine, tryptophan, lysine, magnesium acetate, serine, proline, sodium acetate, trihydrate, sodium chloride, sodium dihydrogen, phosphate dihydrate, sodium hydroxide, soya oil - emulsion for infusion - calcium chloride dihydrate 0.353 g/l phenylalanine 2.81 g/l potassium acetate 2.354 g/l histidine 1 g/l arginine 2.16 g/l aspartic acid 1.2 g/l alanine 3.88 g/l threonine 1.46 g/l triglycerides medium chain 20 g/l valine 2.08 g/l zinc acetate dihydrate 5.3 g/l glucose 64 g/l glutamic acid 2.8 g/l glycine 1.32 g/l methionine 1.57 g/l isoleucine 1.87 g/l l-tryptophan 0.46 g/l lysine 1.81 g/l magnesium acetate 0.515 g/l serine 2.4 g/l leucine 2.5 g/l proline 2.72 g/l sodium acetate trihydrate 0.435 g/l sodium chloride 0.865 g/l sodium dihydrogen phosphate dihydrate 0.936 g/l sodium hydroxide 0.64 g/l soya oil 20 g/l - blood substitutes and perfusion solutions

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.69 mg - capsule, enteric - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); triethyl citrate; titanium dioxide; mannitol; hypromellose; gelatin; stearoyl macrogolglycerides; maize starch; polysorbate 80; purified talc; iron oxide yellow; sucrose; diacetylated monoglycerides; purified water; dimeticone 350; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory,drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 43.37 mg - capsule, enteric - excipient ingredients: maize starch; dimeticone 350; gelatin; purified water; hypromellose; sucrose; methacrylic acid - ethyl acrylate copolymer (1:1); titanium dioxide; polysorbate 80; triethyl citrate; purified talc; iron oxide yellow; diacetylated monoglycerides; mannitol; stearoyl macrogolglycerides; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory,drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone sodium phosphate oral solution (15 mg prednisolone per 5 ml) is indicated in the following conditions: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephritic syndrome, without uremia. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); c

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone sodium phosphate 10 mg in 1 ml - primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. congenital adrenal hyperplasia. nonsuppurative thyroiditis. hypercalcemia associated with cancer. as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: post-traumatic osteoarthritis. synovitis of osteoarthritis. rheumatoid arthritis, including juvenile

Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - sodium chloride, quantity: 6 mg/ml; calcium chloride dihydrate, quantity: 0.27 mg/ml; potassium chloride, quantity: 0.4 mg/ml; sodium lactate, quantity: 3.12 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. the solution may also be used as a solvent for intravenously administrated drugs where compatibility has been established. compound sodium lactate is particularly suitable for the replacement of extracellular fluid loss when isotonic dehydration is evident and in burn therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - disodium edetate, quantity: 30 mg/ml - injection, concentrated - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) 1. disodium edetate is particularly effective in treating lead accumulation and lead poisoning. this is especially so where there is a concomitant hypercalcaemic problem (refer "indications (2)"). however it must be noted that disodium edetate is equally effective with calcium disodium edetate in removing heavy metals, even in the absence of hypercalcaemia. for patients with elevated serum calcium or hypermobility of their body pools of calcium where there may be transiently or prolonged raised serum calcium (see "indications (2)"), the edta of choice for removing heavy metals may be disodium edetate. there are no recognised safe limits for lead intoxication. lead poisoning may occur by ingestion or inhalation of lead dust or fumes. poisoning is manifested by a metallic taste, anorexia, irritability, apathy, abdominal colic, vomiting, diarrhoea, cons